Digital pathology is undergoing a fundamental transformation. For over a century, pathologists have manually examined glass slides under microscopes to diagnose cancer and other diseases. Today, whole slide imaging scanners digitize these specimens into gigapixel images, and AI algorithms like those from Path.AI can analyze them in minutes with objectivity and reproducibility that exceed human performance on specific tasks. MedicalCloudAIHub.com integrates Path.AI for all digital pathology workflows.
What Path.AI Analyzes
Path.AI’s deep learning algorithms automatically quantify tumor cellularity, mitotic rate, PD-L1 expression, HER2 status, microsatellite instability, and Gleason grade from whole slide images. These quantitative measurements provide objective, reproducible assessments that reduce inter-observer variability — one of the most persistent challenges in anatomic pathology.
Oncology Applications
Path.AI has developed validated algorithms for prostate cancer Gleason scoring, breast cancer biomarker quantification (ER, PR, HER2, Ki-67), colorectal cancer staging and microsatellite instability testing, lung cancer subtype classification, and hematological malignancy diagnosis. Each algorithm has been validated against expert pathologist consensus across diverse patient cohorts.
Integration with MedicalCloudAIHub
When a whole slide image arrives at MedicalCloudAIHub, our orchestration engine automatically routes it to Path.AI for analysis. Results are returned as structured FHIR Observation resources and linked to the patient’s DiagnosticReport, making quantitative pathology data immediately accessible in your EHR system.
Access Path.AI for $1,000/month
MedicalCloudAIHub.com — contact@medicalcloudaihub.com | SCMDSD LLC, Cheyenne, Wyoming, USA